How Are Research Peptides Made?

Published August 28, 2026 · Artemis Labs

Research Buyer FAQ › What Research Peptides Are › How Peptides Are Made

Nearly every research peptide is built by chemical synthesis: one amino acid at a time, on a solid support, in a repeating cycle. The finished chain is cut free, purified, and freeze-dried into the powder in the vial. The method also explains the impurities — they are near-copies of the target — which is why the purity figure matters.

How this page was built. This page describes the standard chemistry the whole industry uses, as documented in the peer-reviewed literature cited under References. It describes no individual vendor’s production process — including our own. Where the method has a consequence a buyer can check, the page links to the check.

What is solid-phase peptide synthesis?

Solid-phase peptide synthesis — SPPS — is the method used to make almost all research peptides, and the idea behind it is simple: build the chain one amino acid at a time while it stays anchored to tiny plastic beads. A peptide is a chain of amino acids joined in an exact order. In SPPS, the first amino acid is attached to a bead of resin, the next one is added to the end of the chain, the leftover chemicals are washed away, and the cycle repeats until the chain is complete. Anchoring the growing chain to a solid bead is what makes the washing possible — the product stays put while everything else rinses off.

The technique dates to the 1960s and has been refined ever since; the version used almost everywhere today is called Fmoc SPPS, after the chemical group that protects the growing end of the chain between steps (PMID 26785684). Reviews of the field describe it as the standard route for peptides of the length research catalogs carry.

Why does the chain have to be built one step at a time?

Because amino acids are reactive at both ends, and an uncontrolled mixture would join them in random order. The chemistry only produces the exact sequence if each addition is forced to happen at one place: the free end of the growing chain. That control comes from protecting groups — removable chemical caps that block every reactive spot except the one the chemist wants to react. Each cycle of the synthesis is the same three moves: remove the cap from the end of the chain, couple the next amino acid onto it, wash. Then the new amino acid’s own cap comes off and the cycle runs again (PMID 26785684).

A machine can run this loop automatically, which is why peptide synthesis scales. But the loop has a built-in weakness: no chemical step is ever perfect, and the errors it leaves behind are very particular.

Why are truncated and deletion sequences the characteristic impurities?

Because when a coupling step fails on one bead, that bead’s chain is now missing one amino acid — and the synthesis keeps going anyway. The result at the end of the run is a mixture: mostly the correct full-length chain, plus a family of close relatives — chains missing one amino acid (deletion sequences), chains that stopped growing early (truncated sequences), and chains with a chemically altered amino acid. The published impurity literature for synthetic peptides catalogs exactly these families as the expected by-products of the method (PMID 25044089).

The arithmetic is unforgiving on long chains. If each coupling works 99% of the time, a 30-step chain comes out roughly 74% right before purification — the small errors compound. And because a deletion sequence differs from the target by a single amino acid, it behaves almost identically, which makes it hard to separate out. This is the whole reason a purity percentage exists and matters: it is the measure of how much of the vial is the exact target chain rather than one of its near-copies. What that percentage measures — and what it leaves out — is covered in what a 99% HPLC purity figure measures.

How is the finished peptide purified?

By cutting it off the beads with strong acid, then separating the target chain from its near-copies by chromatography. The acid cleavage step also strips the last protecting groups. The crude mixture then runs through preparative HPLC, which separates chains by how they interact with a column, and the fractions containing the target are collected. One side effect of the acid chemistry is worth knowing as a buyer: the finished peptide usually comes out paired with leftover acid as a counterion, most often trifluoroacetate (TFA), which adds weight to the powder without being peptide. That is part of why a vial’s labelled milligrams and its actual peptide content are two different numbers — explained in net peptide content versus label mg.

Why is the finished peptide freeze-dried?

Because a dry solid keeps and a solution does not. After purification the peptide is dissolved in water, frozen, and placed under vacuum so the ice turns directly to vapor and leaves the vial. What remains is a light, porous solid — the cake or thin film a buyer sees. The process is called lyophilisation (defined in our glossary entry for lyophilised), and the manufacturing literature is explicit about why it is used: degradation chemistry runs on water, so removing the water is what makes long storage possible (PMID 10967427). What that means for shelf life and refrigeration is its own page: lyophilised peptide shelf life and storage temperature.

Why does peptide material vary so much between makers?

Because the same chemistry can be run at very different scales, with very different levels of control, and the differences land in the vial. Peptide synthesis at production scale is a demanding industrial process — the published process-chemistry literature describes purification as one of its largest costs and hardest steps (PMID 30900880). Chain length multiplies everything: a long sequence means more cycles, more chances for a failed coupling, more near-copies to remove, and more expensive purification. That is a structural reason why two vials with the same compound name can differ in cost and in what is actually inside them.

For a buyer, the practical consequence is that the origin story on a website is not the check — the batch’s measured numbers are. A Certificate of Analysis ties one production batch to one set of test results, and how to read one critically is covered in Certificates of Analysis & Verification.

Are peptides ever made biologically instead?

Yes — long chains are often grown rather than built. Chemical synthesis gets harder as chains get longer, so proteins and the longest peptides are more often produced recombinantly: the genetic instructions for the chain are placed into cells, and the cells manufacture it. For the chain lengths typical of research peptide catalogs, the field’s reviews describe chemical synthesis as the dominant route (PMID 26785684, PMID 30900880). Either way, what a buyer can verify is the same: not the production method, but the analytical evidence — identity and purity, measured on the batch in hand.

What research peptides are as a class — and what they are not — lives on the parent page, What Research Peptides Are. This page is one section of the full Artemis Labs research-buyer FAQ.

References

  1. Behrendt R, White P, Offer J. “Advances in Fmoc solid-phase peptide synthesis.” J Pept Sci. 2016;22(1):4–27. PMID 26785684 · doi:10.1002/psc.2836
  2. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. “Related impurities in peptide medicines.” J Pharm Biomed Anal. 2014;101:2–30. PMID 25044089 · doi:10.1016/j.jpba.2014.06.012
  3. Wang W. “Lyophilization and development of solid protein pharmaceuticals.” Int J Pharm. 2000;203(1–2):1–60. PMID 10967427 · doi:10.1016/s0378-5173(00)00423-3
  4. Isidro-Llobet A, Kenworthy MN, Mukherjee S, Kopach ME, et al. “Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production.” J Org Chem. 2019;84(8):4615–4628. PMID 30900880 · doi:10.1021/acs.joc.8b03001

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.